INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $633,000 | +146.3% | 27,435 | +163.7% | 0.00% | – |
| Q4 2020 | $257,000 | -91.7% | 10,404 | -84.0% | 0.00% | -100.0% |
| Q2 2020 | $3,106,000 | -54.7% | 64,829 | -40.4% | 0.00% | -63.6% |
| Q1 2020 | $6,851,000 | -55.9% | 108,821 | -21.3% | 0.01% | -45.0% |
| Q4 2019 | $15,522,000 | +116.7% | 138,264 | +13.6% | 0.02% | +100.0% |
| Q3 2019 | $7,164,000 | +1.9% | 121,744 | +5.5% | 0.01% | 0.0% |
| Q2 2019 | $7,033,000 | -18.8% | 115,349 | +14.6% | 0.01% | -23.1% |
| Q1 2019 | $8,660,000 | -3.2% | 100,630 | +13.4% | 0.01% | -18.8% |
| Q4 2018 | $8,946,000 | -9.5% | 88,761 | +13.5% | 0.02% | +6.7% |
| Q3 2018 | $9,883,000 | +50.1% | 78,211 | -0.3% | 0.02% | +36.4% |
| Q2 2018 | $6,585,000 | +37.0% | 78,476 | +0.4% | 0.01% | +22.2% |
| Q1 2018 | $4,808,000 | +141.5% | 78,152 | +129.4% | 0.01% | +125.0% |
| Q4 2017 | $1,991,000 | +805.0% | 34,073 | +1648.2% | 0.00% | +300.0% |
| Q1 2017 | $220,000 | – | 1,949 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |